Video Interview: O.B. Parrish, Chairman of the Board & CEO, The Female Health Company

NASDAQ CEO Signature Series Broadcasted From the NASDAQ MarketSite


NEW YORK, July 14, 2009 (GLOBE NEWSWIRE) -- Veteran business journalist Joya Dass joins O.B. Parrish, President & CEO, The Female Health Company (FHCO) to discuss the company's industry, strategy, financials and positioning.

Click here to view video:

http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=37762&k=500D12F3D9AF11F5FC2F5B7001A933B8

O.B. Parrish, one of the Company's founders, has served as the Chairman of the Board and Chief Executive Officer since 1996. Mr. Parrish has spent his career in the pharmaceutical industry. Previously, Mr. Parrish was President of the Global Pharmaceutical Group of G. D. Searle. Prior to that, Mr. Parrish was the President of Searle International, the foreign sales operation of Searle. Prior to joining Searle, Mr. Parrish was Executive Vice President of Pfizer's International Division.

Mr. Parrish received his B.S. degree from Lawrence University, where he currently serves as a trustee. He obtained his M.B.A. from the University of Chicago.

About The Female Health Company

The Female Health Company, which trades on the NASDAQ-CM stock exchange under the symbol "FHCO", owns certain world-wide rights to the Female Condoms, FC1 and FC2. The Female Condom is a revolutionary, female initiated option offering women dual protection against both sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. FHCO has the only FDA approved female condoms (FC1 and FC2) in the world. Condoms, male and female, are the only means of preventing HIV/AIDS transmission via sexual intercourse. With the unfortunate development failures of likely prevention alternatives (microbicides and a HIV/AIDS vaccine), viable prevention alternatives to condoms appear to be years away.

With STI prevention being the product's primary use, FHCO's main market is currently the public sector, which distributes the Female Condom in more than 90 countries world-wide. The public sector is the market in which various organizations supply critical products for distribution, at low cost or no cost, to those who need but cannot afford to buy such products themselves. The public sector buyers include large international agencies such as UNFPA (United Nations Population Fund) and USAID (United States Agency for International Development), governmental Ministries of Health, state and local health agencies and non-governmental agencies. The global condom market (public sector and private) is estimated to be $3 billion, or 13-14 billion units annually. Approximately 10 billion of the units are purchased by the public sector.

The global distribution of HIV/AIDS cases are now 54% male and 46% female, with females comprising more than 50% of newly diagnosed cases. In sub-Saharan Africa, new diagnoses are as much as 70% female. The female condom is not seen as competing with the male condom, but rather as an alternative to the male condom, or to unprotected sex. Female condoms (FC) are available in more than 100 countries. UNAIDS estimates that the public sector prevention market for male and female condoms will reach 19 billion units annually by 2015.

The Female Health Company (FHCO), which has been profitable since FY 2006, has demonstrated significant growth in unit sales, revenues and profitability over the past five years. The Company has a strong balance sheet, no debt and is cash flow positive.

For more information about NASDAQ CEO Signature Series interviews, call 978/461-3141

The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839

GlobeNewswire